Aileron Therapeutics (NASDAQ:ALRN) inks an agreement with Lincoln Park Capital Fund, under which latter will purchase up to $15M of its common stock over a period of 36 months.

Lincoln Park made an initial purchase of $500K at $1.36/share.

Net proceeds will be used for general corporate purposes and extending cash runway to support ALRN-6924 clinical development strategy.


Source link